Abstract: An anti-IL-22 antibody or antibody fragment that binds to both human IL-22 and a mammalian IL-22 as well as modified anti-IL-22 antibodies and antibody fragments. Pharmaceutical compositions and kits comprising the antibody or antibody fragment are also provided. Also provided are methods for treatment of various IL-22 mediated conditions and diseases.

Abstract: A method for producing levulinic acid from lignocellulosic biomass comprising hemicellulose including one or more six carbon chain compound precursors comprises the steps of hydrolyzing the lignocellulosic biomass to form a first phase comprising partially hydrolyzed lignocellulosic biomass including cellulose and lignin and a second phase comprising one or more five carbon chain sugars and one or more six carbon chain sugars from degradation of the hemicellulose, separating the first phase from the second phase, and converting at least a portion of the one or more six carbon chain sugars to levulinic acid.

Abstract: A method for producing levulinic acid from lignocellulosic biomass comprising hemicellulose including one or more six carbon chain compound precursors comprises the steps of hydrolyzing the lignocellulosic biomass to form a first phase comprising partially hydrolyzed lignocellulosic biomass including cellulose and lignin and a second phase comprising one or more five carbon chain sugars and one or more six carbon chain sugars from degradation of the hemicellulose, separating the first phase from the second phase, and converting at least a portion of the one or more six carbon chain sugars to levulinic acid.

Abstract: The invention generally relates to compositions and methods for chemically mechanically polishing a substrate, including a polishing accelerator, which is normally one or more oxidizers, an abrasive material, and chelating particles and/or metal-absorbent clay material. In addition, the invention can also involve methods of forming chelator particles and methods of separating metal-containing ions from polishing and/or etching solutions after polishing and/or etching.

Abstract: A disposable warmer cartridge is used to heat fluids to be infused to the patient to prevent hypothermia in the patient. The cartridge has in its chamber a pair of spaced in parallel electrodes that have substantially the same dimension. When RF power is fed to the electrodes, an alternating electric field is generated between the electrodes to directly heat the fluid that is in the chamber. The heating of the fluid is achieved in a substantially instantaneous manner by controlling the energization of the electrodes through the distributed impedance of the electric field between the electrodes. Heat is readily controlled by modulating the RF power fed to the electrodes. Feedback to control the temperature of the fluid in the cartridge may be provided by non-contact and direct contact sensor(s).

Abstract: A tube is bent having a curved portion with a variable radius extending between first and second ends. The curved portion includes a circular arc portion with a constant radius and a clothoid transition portion with a variable radius. The circular arc portion extends from the first end toward a point of integration. At the point of integration, the circular arc portion merges with the transition portion. The transition portion extends from the point of integration to the second end. As the transition portion extends from the point of integration, its radius of curvature increases over its arc length, thereby, improving the quality of the bent tube by gradually bending the tube over a longer distance, thereby reducing local stresses on the bent portion of the tube.

Abstract: The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region.

Abstract: Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and/or stabilizing hypoxia-inducible factor-1? (HIF-1?). HIF-1? is known to provide a neuroprotective benefit under ischemic conditions. In another embodiment, the method is accomplished by differentially reducing, inhibiting or preventing the increased expression of selected genes caused by neurological disorders. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease, Huntington's disease, thalassemia or stroke, or those patients having head or spinal cord injury.

Abstract: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.

Abstract: A method for delivering a melanocortin-4 receptor agonist to a mammalian subject, includes administering the melanocortin-4 receptor agonist to a tissue inside the nasal cavity or sinuses of the mammalian subject. In some instances, the melanocortin-4 receptor agonist includes a guanidine functional group.

Abstract: To reduce the amount of air input to a patient warming blanket, when the blanket is of a size that does not require the full amount of air output from a convective warmer for optimal pressurization, a regulator is provided to the inlet of the blanket to restrict the amount of air input to the blanket, thereby reducing the airflow rate to one that is appropriate for the optimal inflation or pressurization of the warming blanket. Respective regulators that allow different amounts of air under pressure to pass therethrough may be correspondingly fitted to blankets of different sizes and/or dimensions. Each regulator fitted to the inlet of the blanket may be configured in the form of an adapter with multiple orifices for passage of air, or a filter made of an air permeable material having a preselected porosity.

Abstract: The present invention provides a method for delivering polynucleotide agents, particularly oligonucleotides, to the CNS of a mammal by way of a neural pathway originating in the nasal cavity or through a neural pathway originating in an extranasal tissue that is innervated by the trigeminal nerve.

Abstract: A convective warmer to which blankets of different dimensions may be connected is capable of providing air to the various blankets at flow rates that optimally inflate those blankets to achieve the optimal clinical result for the patients covered by those blankets. The blanket connected to the warmer may range from a full size adult warming blanket to a pediatric or neonate warming blanket. There is provided on each blanket a code, marking or marker, to be read by a sensor(s) provided at the outlet of the warmer, that identifies the type of blanket when the blanket is coupled to the warmer. Consequently, heated air may be automatically output by the warmer to the blanket at the appropriate flow rate of that blanket to optimally inflate the blanket without any need for intervention by a user. In addition to being used to control the flow rate of the heated air, the code from the blanket may also be used to control the temperature of the heated air to be input to the blanket.

Abstract: A method for delivering a polypeptide to the central nervous system of a mammal is provided. The method involves attaching the polypeptide to an antibody or an antibody fragment and administering the fusion polypeptide intranasally, for delivery to the central nervous system. Methods of treatment are also provided, where a therapeutically effective amount of the composition is delivered to the nasal cavity of a mammal.

Abstract: A convective warmer to which blankets of different dimensions may be connected is capable of providing air to the various blankets at flow rates that optimally inflate those blankets to achieve the optimal clinical result for the patients covered by those blankets. The blanket connected to the warmer may range from a full size adult warming blanket to a pediatric warming blanket. The convection warmer may have multiple fixed air flow rates each selectable by a user, via switch(es) either electronically or mechanically. For the electronic selection of a given flow rate, a motor adaptable to rotate a different speeds is used. To vary the flow rate mechanically, a valve is controlled to vary the amount of air that may pass to the blanket. Instead of different fixed flow rates, variable air flow rates, selectable by the user, may be used. Also, a feedback circuit that maintains the pressure sensed at the outlet of the warmer to a preset pressure may be used to eliminate the need for user intervention.

Abstract: A convective warmer to which blankets of different dimensions may be connected is capable of providing air to the various blankets at flow rates that optimally inflate those blankets to achieve the optimal clinical result for the patients covered by those blankets. The blanket connected to the warmer may range from a full size adult warming blanket to a pediatric warming blanket. The convection warmer may have multiple fixed air flow rates each selectable by a user, via switch(es) either electronically or mechanically. For the electronic selection of a given flow rate, a motor adaptable to rotate a different speeds is used. To vary the flow rate mechanically, a valve is controlled to vary the amount of air that may pass to the blanket. Instead of different fixed flow rates, variable air flow rates, selectable by the user, may be used. Also, a feedback circuit that maintains the pressure sensed at the outlet of the warmer to a preset pressure may be used to eliminate the need for user intervention.

Abstract: The present invention is directed to a method for delivering cytokines to the central nervous system and the lymphatic system by way of a tissue innervated by the trigeminal nerve and/or olfactory nerve. Cytokines include tumor necrosis factors, interleukins, interferons, particularly interferon-? and its muteins such as IFN-?ser17. Such a method of delivery can be useful in the treatment of central nervous system disorders, brain disorders, proliferative, viral, and/or autoimmune disorders such as Sjogren's disorder.

Abstract: Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1? (HIF-1?). HIF-1? is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized.

Abstract: Methods and compositions for increasing the efficacy of an agent that directly or indirectly affects a muscarinic receptor by administering a pyrophosphate analog. Methods and compositions for protecting a pharmacological agent in a formulation, comprising combining the pharmacological agent with at least one pyrophosphate analog. Methods and compositions for increasing the efficacy of a neurologic agent by administering at least one pyrophosphate analog. Methods and compositions for increasing the efficacy of an agent that neither directly nor indirectly affects a muscarinic receptor by administering at least one pyrophosphate analog.

Abstract: Methods and compositions for protecting and treating a muscarinic receptor in an animal or plant from bacterial, fungal, algo or algae infections through administration of at least one pyrophosphate analog.